VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary
VolitionRx Limited Appoints Two New Directors
VolitionRx Limited Announces Full Fiscal Year 2020 Financial Results and Business Update
New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis
VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update
VolitionRx Limited to Present at Conferences in March 2021
VolitionRx Limited Announces Closing of $20 Million Underwritten Public Offering of Common Stock
VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization Efforts
